6 research outputs found
Forensic application of a multiplex PCR system for the typing of pig STRs
The Animal Type Pig PCR Amplification kit (Biotype AG, Dresden, Germany), a multiplex PCR system that allows the simultaneous
amplification of 11 tetrameric short tandem repeats (STRs) and an Amelogenin-like locus for individual identification and sexing of pig (sus scrofa), was employed in the investigation of an alleged case of veterinary malpractice. A veterinarian responsible for collecting random blood samples as part of the program for the serological surveillance of swine vesicular disease (SVD) was accused of having drawn multiple samples from a single sow. STR typing of serum left overs from SVD testing strongly supported the conclusion that all the questioned samples included DNA from the same animal
Haplotype data and mutation rates for the 23 Y-STR loci of PowerPlex® Y 23 System in a Northeast Italian population sample
Toward Male Individualization with Rapidly Mutating Y-Chromosomal Short Tandem Repeats
Relevant for various areas of human genetics, Y-chromosomal short tandem repeats (Y-STRs) are commonly used for testing close paternal relationships among individuals and populations, and for male lineage identification. However, even the widely used 17-loci Yfiler set cannot resolve individuals and populations completely. Here, 52 centers generated quality-controlled data of 13 rapidly mutating (RM) Y-STRs in 14,644 related and unrelated males from 111 worldwide populations. Strikingly, >99% of the 12,272 unrelated males were completely individualized. Haplotype diversity was extremely high (global: 0.9999985, regional: 0.99836-0.9999988). Haplotype sharing between populations was almost absent except for six (0.05%) of the 12,156 haplotypes. Haplotype sharing within populations was generally rare (0.8% nonunique haplotypes), significantly lower in urban (0.9%) than rural (2.1%) and highest in endogamous groups (14.3%). Analysi
MEDICAL SCIENCE. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction
A multicentre, randomised, open trial with a 2 x 2 factorial design was conducted to compare the benefits and risks of two thrombolytic agents, streptokinase (SK, 1\ub75 MU infused intravenously over 30-60 min) and alteplase (tPA, 100 mg infused intravenously over 3 h) in patients with acute myocardial infarction admitted to coronary care units within 6 h from onset of symptoms. The patients were also randomised to receive heparin (12 500 U subcutaneously twice daily until discharge from hospital, starting 12 h after beginning the tPA or SK infusion) or usual therapy. All patients without specific contraindications were given atenolol (5-10 mg iv) and aspirin (300-325 mg a day). The end-point of the study was the combined estimate of death plus severe left ventricular damage. 12 490 patients were randomised to four treatment groups (SK alone, SK plus heparin, tPA alone, tPA plus heparin). No specific differences between the two thrombolytic agents were detected as regards the combined end-point (tPA 23\ub71%; SK 22\ub75%; relative risk 1\ub704, 95% Cl 0\ub795-1\ub713), nor after the addition of heparin to the aspirin treatment (hep 22\ub77%, no hep 22\ub79%; RR 0\ub799, 95% Cl 0\ub791-1\ub708). The outcome of patients allocated to the four treatment groups was similar with respect to baseline risk factors such as age, Killip class, hours from onset of symptoms, and site and type of infarct. The rates of major in-hospital cardiac complications (reinfarction, post-infarction angina) were also similar. The incidence of major bleeds was significantly higher in SK and heparin treated patients (respectively, tPA 0\ub75%, SK 1\ub70%, RR 0\ub757, 95% Cl 0\ub738-0\ub785; hep 1\ub70%, no hep 0\ub76%, RR 1\ub764, 95% Cl 1\ub709-2\ub745), whereas the overall incidence of stroke was similar in all groups. SK and tPA appear equally effective and safe for use in routine conditions of care, in all infarct patients who have no contraindications, with or without post-thrombolytic heparin treatment. The 8\ub78% hospital mortality of the study population (compared with approximately 13% in the control cohort of the GISSI-1 trial) indicates the beneficial impact of the proven acute treatments for AMI. \ua9 1990
Toward Male Individualization with Rapidly Mutating Y-Chromosomal Short Tandem Repeats
Relevant for various areas of human genetics,
Y-chromosomal short tandem repeats (Y-STRs) are com-
monly used for testing close paternal relationships among
individuals and populations, and for male lineage iden-
tification. However, even the widely used 17-loci Yfiler
set cannot resolve individuals and populations completely.
Here, 52 centers generated quality-controlled data of 13
rapidly mutating (RM) Y-STRs in 14,644 related and
unrelated males from 111 worldwide populations. Strik-
ingly, >99% of the 12,272 unrelated males were com-
pletely individualized. Haplotype diversity was extremely
high (global: 0.9999985, regional: 0.99836\u20130.9999988).
Haplotype sharing between populations was almost ab-
sent except for six (0.05%) of the 12,156 haplotypes.
Haplotype sharing within populations was generally rare
(0.8% nonunique haplotypes), significantly lower in ur-
ban (0.9%) than rural (2.1%) and highest in endogamous
groups (14.3%). Analysis of molecular variance revealed
99.98% of variation within populations, 0.018% among
populations within groups, and 0.002% among groups. Of
the 2,372 newly and 156 previously typed male relative
pairs,29% were differentiated including 27% of the 2,378
father\u2013son pairs. Relative to Yfiler, haplotype diversity
was increased in 86% of the populations tested and over-
all male relative differentiation was raised by 23.5%. Our
study demonstrates the value of RM Y-STRs in identifying
and separating unrelated and related males and provides a
reference database